Active, not recruitingPhase 2NCT03933904
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
Studying Castleman disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pennsylvania
- Principal Investigator
- Joshua Brandstadter, MD, PhD, MSc, M.D., PhDUniversity of Pennsylvania
- Intervention
- Sirolimus(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 2-80 years · All sexes
- Timeline
- 2019 – 2026
Study locations (2)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03933904 on ClinicalTrials.govOther trials for Castleman disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07085039Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman DiseaseUniversity of Pennsylvania
- RECRUITINGPHASE2NCT06052618Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05907759Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNational Cancer Institute (NCI)
- RECRUITINGNCT06720870An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life ContextIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT05081141HHV8 and Solid Organ TransplantationFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT03300830Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseNational Cancer Institute (NCI)
- RECRUITINGNCT02817997International Registry for Patients With Castleman DiseaseUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT01552434Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer Center